Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease

Int J Cardiol. 2016 Apr 15:209:181-3. doi: 10.1016/j.ijcard.2016.02.005. Epub 2016 Feb 2.

¹ Cardiovascular Diseases, Mayo Clinic, Rochester, MN, United States; Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, United States. Electronic address: noseworthy.peter@mayo.edu.
² Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, United States.
³ Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, United States; Division of Health Care Policy and Research, Department of Health Services Research, Rochester, MN, United States; Optum Labs, Cambridge, MA, United States.
⁴ Cardiovascular Diseases, Mayo Clinic, Rochester, MN, United States.

No abstract available

Keywords: Bleeding; NOAC; Stroke; Valvular heart disease; Warfarin.

Publication types